20:07 , Jul 13, 2018 |  BC Week In Review  |  Clinical News

EMA's CHMP recommends CAR Ts, rare disease therapies

EMA's CHMP recommended for approval Kymriah tisagenlecleucel and Yescarta axicabtagene ciloleucel, the first two CAR T therapies backed by the committee. CHMP also recommended a handful of other Orphan drug candidates, including Cablivi caplicizumab, a key...
20:06 , Jul 13, 2018 |  BC Week In Review  |  Company News

FTC approves Takeda's Shire takeover

Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) said it received "unconditional clearance" from the Federal Trade Commission (FTC) regarding its proposed acquisition of Shire plc (LSE:SHP; NASDAQ:SHPG). In May, Takeda struck a deal to acquire Shire for...
18:58 , Jul 13, 2018 |  BC Week In Review  |  Company News

Takeda declines to respond to reports regarding sale of Osaka headquarters

Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) declined to respond to reports that it plans to sell its Osaka headquarters for about ¥60 billion ($542 million) to finance its acquisition of Shire plc (LSE:SHP; NASDAQ:SHPG) and told...
03:04 , Jun 30, 2018 |  BioCentury  |  Finance

Eyes on launches

The annual summer slowdown isn’t restricted to just the stock market this year, as the clinical catalyst calendar also appears to be on holiday in 3Q18. Buysiders are therefore turning their attention to a spate of...
02:23 , Jun 30, 2018 |  BioCentury  |  Product Development

Defining access potential - before it’s too late

We see it everywhere: confirmation bias. Innovators believe in a drug, find the evidence to support its value, and dismiss or ignore the facts challenging their preferred story. But confirmation bias is particularly problematic thanks...
20:20 , Jun 29, 2018 |  BC Extra  |  Company News

CHMP backs CAR Ts, Orphan candidates

EMA's CHMP recommended for approval Kymriah tisagenlecleucel and Yescarta axicabtagene ciloleucel, the first two CAR T therapies backed by the committee. CHMP also recommended a handful of other Orphan drug candidates, including Cablivi caplicizumab, a...
18:33 , Jun 29, 2018 |  BC Week In Review  |  Financial News

Tricida, Translate Bio, Forty Seven and Entera price IPOs

Among three well-funded biotechs that priced IPOs, Tricida Inc. (NASDAQ:TCDA) had by far the best first-day performance on June 28, posting a 37% gain, while Translate Bio Inc. (NASDAQ:TBIO) and Forty Seven Inc. (NASDAQ:FTSV) each...
14:42 , Jun 29, 2018 |  BC Week In Review  |  Financial News

Precision BioSciences raises $110M in series B

Genome editing company Precision BioSciences Inc. (Durham, N.C.) raised $110 million in an oversubscribed series B round led by new investor ArrowMark Partners. Other new Investors included Franklin Templeton, Cowen Healthcare Investments, Brace Pharma Capital, Pontifax...
05:15 , Jun 28, 2018 |  BC Extra  |  Financial News

Tricida gains, others dip after upsized IPOs

Among three well-funded biotechs that priced IPOs, Tricida Inc. (NASDAQ:TCDA) had by far the best first-day performance Thursday, posting a 37% gain, while Translate Bio Inc. (NASDAQ:TBIO) and Forty Seven Inc. (NASDAQ:FTSV) each lost ground. All...
19:46 , Jun 26, 2018 |  BC Extra  |  Financial News

Precision BioSciences raises $110M in series B

Genome editing company Precision BioSciences Inc. (Durham, N.C.) raised $110 million in an oversubscribed series B round led by new investor ArrowMark Partners. Other new Investors included Franklin Templeton, Cowen Healthcare Investments, Brace Pharma Capital, Pontifax...